Providers' Experiences and Perspectives in Treating Patients With Co-Occurring Opioid and Stimulant Use Disorders in the Hospital
Overview
Authors
Affiliations
Background: The overdose crisis is increasingly characterized by opioid and stimulant co-use. Despite effective pharmacologic treatment for both opioid use disorder (OUD) and contingency management for stimulant use disorders, most individuals with these co-occurring conditions are not engaged in treatment. Hospitalization is an important opportunity to engage patients and initiate treatment, however existing hospital addiction care is not tailored for patients with co-use and may not meet the needs of this population.
Methods: Semi-structured interviews were conducted with hospital providers about their experiences and perspectives treating patients with opioid and stimulant co-use. We used directed content analysis to identify common experiences and opportunities to improve hospital-based treatment for patients with co-use.
Results: From qualitative interviews with 20 providers, we identified 4 themes describing how co-use complicated hospital-based substance use treatment: (1) patients' unstable circumstances impacting the treatment plan, (2) co-occurring withdrawals are difficult to identify and treat, (3) providers holding more stigmatizing views of patients with co-use, and (4) stimulant use is often "ignored" in the treatment plans. Participants also described a range of potential opportunities to improve hospital-based treatment of co-use that fall into 3 categories: (1) provider practice changes, (2) healthcare system changes, and (3) development and validation of clinical tools and treatment approaches.
Conclusions: We identified unique challenges providing hospital addiction medicine care to patients who use both opioids and stimulants. These findings inform the development, implementation, and testing of hospital-based interventions for patients with co-use.
Shearer R, Bart G, Beebe T, Virnig B, Shippee N, Winkelman T J Subst Use Addict Treat. 2024; 167:209505.
PMID: 39241929 PMC: 11527587. DOI: 10.1016/j.josat.2024.209505.
Bello J, Xu K, Salas J, Kelly J, Grucza R Drug Alcohol Depend Rep. 2024; 12:100248.
PMID: 39040479 PMC: 11261297. DOI: 10.1016/j.dadr.2024.100248.
No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder.
Tilhou A, Baldwin M, Alves J Am J Prev Med. 2024; 67(3):464-469.
PMID: 38762205 PMC: 11338722. DOI: 10.1016/j.amepre.2024.05.005.